Hironari Matsuda
Overview
Explore the profile of Hironari Matsuda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
21
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Miyashita Y, Tajima K, Izumi K, Matsumoto N, Hayakawa D, Nakamura I, et al.
Cancer Sci
. 2025 Mar;
PMID: 40036147
Osimertinib, a third-generation EGFR-tyrosine kinase inhibitor, is the first-line therapy for lung cancer harboring EGFR mutations. The mechanisms underlying osimertinib resistance are diverse, with approximately half remaining unknown. Epigenetic dysregulation...
2.
Torasawa M, Horinouchi H, Nomura S, Igawa S, Asai M, Ishii H, et al.
J Thorac Oncol
. 2023 Sep;
19(2):325-336.
PMID: 37748690
Introduction: Traditionally, relapsed SCLC has been classified as "sensitive" or "refractory" on the basis of cutoff values (60 or 90 d) for the duration between the last chemotherapy and disease...
3.
Matsuda H, Katayama I, Watanabe T, Komatsu A, Iwakami N, Goto Y, et al.
BMC Infect Dis
. 2023 May;
23(1):285.
PMID: 37142952
Background: Vogesella species are common aquatic Gram-negative rods that were first reported in 1997. Vogesella urethralis bacterium was first isolated from human urine in 2020. Only two cases of disease...
4.
Misawa K, Yasuda H, Matsuda H, Hara M, Ochiai T, Koyama D, et al.
Intern Med
. 2022 Nov;
61(22):3421-3424.
PMID: 36385048
Immune checkpoint inhibitors (ICIs) are widely used for the treatment of various cancers. However, paradoxical exacerbation of neoplasms, referred to as "hyperprogressive disease," has been reported in a proportion of...
5.
Sumiyoshi I, Iwakami S, Hara M, Matsuda H, Takahashi K
Geriatr Gerontol Int
. 2022 Apr;
22(6):490-491.
PMID: 35396911
No abstract available.
6.
Matsuda H, Hara M, Iwakami S, Takahashi K
BMJ Case Rep
. 2021 Apr;
14(4).
PMID: 33906872
This report concerns a patient with skeletal muscle metastases due to lung adenocarcinoma harbouring an echinoderm microtubule-associated protein-like-4 (EML4)-anaplastic lymphoma kinase (ALK) rearrangement, who was successfully treated with lorlatinib after...
7.
Miyashita Y, Hara M, Iwakami S, Matsuda H, Iwakami N, Takahashi K
J Med Case Rep
. 2021 Apr;
15(1):178.
PMID: 33865452
Background: Sarcoidosis is pathologically characterized by the formation of non-necrotizing epithelioid cell granulomas. However, pathological findings of patients with sarcoidosis have rarely revealed necrosis. We report here on a patient...
8.
Nakamura R, Ueno Y, Ando J, Matsuda H, Masuda A, Iiduka K, et al.
J Neurol Sci
. 2016 Apr;
364:6-8.
PMID: 27084205
No abstract available.